Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies. ClinicalTrials.gov record last updated 2026-10-05: recruiting. Enrollment is planned at 695 participants. Primary completion is estimated at 2028-02-07. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd). Registered primary measures: Incidence of Adverse Events (AEs), and Serious Adverse Events (SAEs); Changes from baseline in laboratory findings, electrocardiograms (ECGs), and vital signs; Change from baseline Eastern Cooperative Oncology Group performance status (ECOG PS).